(Q72382597)

English

The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma

scientific article published on 01 April 1994

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8166218%20AND%20SRC:MED&resulttype=core&format=json

26 October 2019

The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8166218%20AND%20SRC:MED&resulttype=core&format=json

26 October 2019

ovarian carcinoma

1 reference

based on heuristic

inferred from title

Michael L. Berman

6

object named as

M Berman

0 references

author name string

W J Hoskins

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8166218%20AND%20SRC:MED&resulttype=core&format=json

26 October 2019

W P McGuire

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8166218%20AND%20SRC:MED&resulttype=core&format=json

26 October 2019

M F Brady

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8166218%20AND%20SRC:MED&resulttype=core&format=json

26 October 2019

H D Homesley

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8166218%20AND%20SRC:MED&resulttype=core&format=json

26 October 2019

W T Creasman

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8166218%20AND%20SRC:MED&resulttype=core&format=json

26 October 2019

H Ball

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8166218%20AND%20SRC:MED&resulttype=core&format=json

26 October 2019

J S Berek

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8166218%20AND%20SRC:MED&resulttype=core&format=json

26 October 2019

language of work or name

1 reference

American Journal of Obstetrics and Gynecology

publication date

1 April 1994

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8166218%20AND%20SRC:MED&resulttype=core&format=json

26 October 2019

American Journal of Obstetrics and Gynecology

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8166218%20AND%20SRC:MED&resulttype=core&format=json

26 October 2019

170

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8166218%20AND%20SRC:MED&resulttype=core&format=json

26 October 2019

974-9; discussion 979-80

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8166218%20AND%20SRC:MED&resulttype=core&format=json

26 October 2019

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8166218%20AND%20SRC:MED&resulttype=core&format=json

26 October 2019

Cancer statistics, 1993

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2894%2970090-7

7 January 2021

A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma. A Gynecologic Oncology Group Study

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2894%2970090-7

7 January 2021

Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2894%2970090-7

7 January 2021

Randomised trial comparing two combination chemotherapy regimens (Hexa-CAF vs CHAP-5) in advanced ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2894%2970090-7

7 January 2021

Advanced ovarian adenocarcinoma. A prospective clinical trial of melphalan (L-PAM) versus combination chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2894%2970090-7

7 January 2021

A randomized trial comparing cisplatin plus cyclophosphamide versus cisplatin, doxorubicin, and cyclophosphamide in advanced ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2894%2970090-7

7 January 2021

Therapy of stage III (optimal) epithelial carcinoma of the ovary with melphalan or melphalan plus Corynebacterium parvum (a Gynecologic Oncology Group Study)

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2894%2970090-7

7 January 2021

The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2894%2970090-7

7 January 2021

Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma: a Gynecologic Oncology Group Study

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2894%2970090-7

7 January 2021

Identifiers

10.1016/S0002-9378(94)70090-7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8166218%20AND%20SRC:MED&resulttype=core&format=json

26 October 2019

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8166218%20AND%20SRC:MED&resulttype=core&format=json

26 October 2019

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q72382597&oldid=1753094495"